Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kashif M Munir

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Expert Opinion on Pharmacotherapy|September 5, 2015
The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitusKashif M Munir, Stephen N Davis
Circulation Research|April 27, 2013
Distinct mechanisms for globular adiponectin that integrate vascular and metabolic actions of insulin to help maintain coordinated cardiovascular and glucose homeostasisKashif M Munir, Michael J Quon
Expert Opinion on Pharmacotherapy|April 29, 2017
Diabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose?Kashif M Munir, Elizabeth M Lamos
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|August 8, 2014
Cushing disease: highlighting the importance of early diagnosis for both de novo and recurrent disease in light of evolving treatment patternsElizabeth M Lamos, Kashif M Munir
Expert Opinion on Pharmacotherapy|August 3, 2023
How close are we to personalized pharmacotherapies and innovative technology for type 1 diabetes management?Kashif M Munir, Stephen N Davis
Case Reports in Endocrinology|March 5, 2016
Thyroid Swelling and Thyroiditis in the Setting of Recent hCG Injections and Fine Needle AspirationElizabeth M Lamos, Kashif M Munir
Clinical Pharmacology : Advances and Applications|May 18, 2016
Differential pharmacology and clinical utility of empagliflozin in type 2 diabetesKashif M Munir, Stephen N Davis
Expert Opinion on Pharmacotherapy|May 24, 2018
Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?Kashif M Munir, Stephen N Davis
Lipids|May 8, 2003
Genetics of obesity: more complicated than initially thoughtAlan R Shuldiner, Kashif M Munir
The American Journal of Medicine|September 12, 2018
Doubling of Hemoglobin A1c on PCSK9 Inhibitor TherapyRaafia Memon, Rana Malek, Kashif M Munir
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Expert Opinion on Pharmacotherapy|September 5, 2015
The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitusKashif M Munir, Stephen N Davis
Circulation Research|April 27, 2013
Distinct mechanisms for globular adiponectin that integrate vascular and metabolic actions of insulin to help maintain coordinated cardiovascular and glucose homeostasisKashif M Munir, Michael J Quon
Expert Opinion on Pharmacotherapy|April 29, 2017
Diabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose?Kashif M Munir, Elizabeth M Lamos
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|August 8, 2014
Cushing disease: highlighting the importance of early diagnosis for both de novo and recurrent disease in light of evolving treatment patternsElizabeth M Lamos, Kashif M Munir
Expert Opinion on Pharmacotherapy|August 3, 2023
How close are we to personalized pharmacotherapies and innovative technology for type 1 diabetes management?Kashif M Munir, Stephen N Davis
Case Reports in Endocrinology|March 5, 2016
Thyroid Swelling and Thyroiditis in the Setting of Recent hCG Injections and Fine Needle AspirationElizabeth M Lamos, Kashif M Munir
Clinical Pharmacology : Advances and Applications|May 18, 2016
Differential pharmacology and clinical utility of empagliflozin in type 2 diabetesKashif M Munir, Stephen N Davis
Expert Opinion on Pharmacotherapy|May 24, 2018
Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?Kashif M Munir, Stephen N Davis
Lipids|May 8, 2003
Genetics of obesity: more complicated than initially thoughtAlan R Shuldiner, Kashif M Munir
The American Journal of Medicine|September 12, 2018
Doubling of Hemoglobin A1c on PCSK9 Inhibitor TherapyRaafia Memon, Rana Malek, Kashif M Munir
Pageof 6